Tevogen Regains $1.00 Nasdaq Bid Price Compliance, Pursues Acquisitions
On March 25, 2026, Tevogen regained compliance with Nasdaq's $1.00 minimum bid price requirement after its common stock closed below $1.00 for 30 consecutive business days. The company plans to pursue targeted acquisitions to expand its immunotherapy and AI platforms and aims to achieve a cash-flow-positive operating model.
1. Nasdaq Compliance Restored
Tevogen received written notice on March 25, 2026 confirming it has satisfied the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), reversing a deficiency first noted on September 23, 2025 after 30 consecutive business days below the threshold and securing continued listing on the Nasdaq Global Market.
2. Strategic Growth and Financial Objectives
The company is evaluating targeted acquisition opportunities to complement its immunotherapy and artificial intelligence platforms, part of a broader effort to transition to a cash-flow-positive operating model while upholding its commitment to affordability and efficiency across its diversified healthcare enterprise.